Abstract:Protein kinases play pivotal roles in various biological functions, influencing cell differentiation, promoting survival, and regulating the cell cycle. The disruption of protein kinase activity is intricately linked to pathways in tumor development. This manuscript explores the transformative impact of protein kinase inhibitors on cancer therapy, particularly their efficacy in cases driven by targeted mutations. Focusing on key tyrosine kinase inhibitors (TKIs) like Bcr-Abl, Epidermal Growth Factor Receptor (EGFR), and Vascular Endothelial Growth Factor Receptor (VEGFR), it targets critical kinase families in cancer progression. Clinical trial details of these TKIs offer insights into their therapeutic potentials. Learning from FDA-approved kinase inhibitors, the review dissects trends in kinase drug development since imatinib's paradigm-shifting approval in 2001. TKIs have evolved into pivotal drugs, extending beyond oncology. Ongoing clinical trials explore novel kinase targets, revealing the vast potential within the human kinome. The manuscript provides a detailed analysis of advancements until 2022, discussing the roles of specific oncogenic protein kinases in cancer development and carcinogenesis. Our exploration on PubMed for relevant and significant TKIs undergoing pre-FDA approval phase III clinical trials enriches the discussion with valuable findings. While kinase inhibitors exhibit lower toxicity than traditional chemotherapy in cancer treatment, challenges like resistance and side effects emphasize the necessity of understanding resistance mechanisms, prompting the development of novel inhibitors like osimertinib targeting specific mutant proteins. The review advocates thorough research on effective combination therapies, highlighting the future development of more selective RTKIs to optimize patient-specific cancer treatment and reduce adverse events.

The Brk protein tyrosine kinase as a therapeutic target in cancer: opportunities and challenges

Putting the BRK on breast cancer: From molecular target to therapeutics

Receptor tyrosine kinases in breast cancer treatment: unraveling the potential

BRK&rdquo;ing&rdquo; Down All We Know About PTK6 in Breast Cancer

Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?

Kinase-targeted cancer therapies: progress, challenges and future directions

Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy

Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives

Expression analysis, molecular docking and molecular dynamics simulations to identify potential BTK inhibitors: strategy for targeting pan-cancer

Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs

Molecular Pathways: Targeting P21-Activated Kinase 1 Signaling in Cancer--opportunities, Challenges, and Limitations.

Therapeutic advances of targeting receptor tyrosine kinases in cancer

Progress in the development of small molecular inhibitors of the Bruton’s tyrosine kinase (BTK) as a promising cancer therapy

Protein Kinases as Tumor Biomarkers and Therapeutic Targets

Recent insights into the therapeutic strategies targeting the pseudokinase PTK7 in cancer

Targeting the RAF–MEK–ERK pathway in cancer therapy

Comprehensive Functional Analysis of the Tousled-Like Kinase 2 Frequently Amplified in Aggressive Luminal Breast Cancers

Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides

Role of TBK1 Inhibition in Targeted Therapy of Cancer

Tyrosine kinase inhibitors: a clinical perspective